Prostate-Specific Antigen
"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
| Descriptor ID |
D017430
|
| MeSH Number(s) |
D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.140.625
|
| Concept/Terms |
Prostate-Specific Antigen- Prostate-Specific Antigen
- gamma-Seminoprotein
- gamma Seminoprotein
- Prostate Specific Antigen
- hK3 Kallikrein
- Kallikrein, hK3
- Semenogelase
- Kallikrein hK3
- Seminin
|
Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".
Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".
This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in this website by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 5 | 7 |
| 2006 | 4 | 1 | 5 |
| 2007 | 6 | 6 | 12 |
| 2008 | 2 | 2 | 4 |
| 2009 | 4 | 1 | 5 |
| 2010 | 2 | 4 | 6 |
| 2011 | 1 | 4 | 5 |
| 2012 | 3 | 5 | 8 |
| 2013 | 3 | 4 | 7 |
| 2014 | 3 | 3 | 6 |
| 2015 | 6 | 2 | 8 |
| 2016 | 3 | 4 | 7 |
| 2017 | 1 | 0 | 1 |
| 2018 | 3 | 3 | 6 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 4 | 4 |
| 2022 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles.
-
Differential Circulating Fungal Microbiome in Prostate Cancer Patients Compared to Healthy Control Individuals. J Immunol Res. 2022; 2022:2574964.
-
Examination of prostate-specific antigen (PSA) screening in military and civilian men: analysis of the 2018 behavioral risk factor surveillance system. Cancer Causes Control. 2022 Mar; 33(3):393-402.
-
Physician Attitudes and Self-reported Practices Toward Prostate Cancer Screening in Black and White Men. Fam Med. 2022 01; 54(1):30-37.
-
A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer. Biomed Pharmacother. 2021 Nov; 143:112226.
-
Barriers and Facilitators to Informed Decision-Making About Prostate Cancer Screening Among Black Men. J Am Board Fam Med. 2021 Sep-Oct; 34(5):925-936.
-
Quality of YouTube Videos on Prostate Cancer Screening for Black Men. J Am Board Fam Med. 2021 Jul-Aug; 34(4):724-731.
-
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer. 2021 08 15; 127(16):2954-2965.
-
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100193.
-
Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial. Cancer Prev Res (Phila). 2020 04; 13(4):367-376.
-
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. J Urol. 2020 Apr; 203(4):743-750.